Herzog Fox & Neeman Represented Foamix Pharmaceuticals Ltd. in Its First Prospectus as a Domestic U.S. Filer

8 April 2018

Herzog Fox & Neeman represented Foamix Pharmaceuticals Ltd., an Israeli bio-tech company, as they successfully filed their first prospectus as a domestic U.S. filer. This SEC filling of a shelf registration statement on Form S-3 in an amount of up to $291 million.

Have a question on this topic? We are here to help

Every case is unique. Let's talk about yours.

More News, Insights & Events

The Broker-Dealer Reform Moves Forward

Global Fund Managers Time to Rethink Your Strategy in Israel

Hypernative $40 million Series B financing

JOIN OUR

Newsletter

Site by Gootte

Disclaimer

The information contained in this web site is provided for informational purposes only and should not be construed as legal advice on any subject matter and should not be relied upon as such. Herzog accepts no responsibility for any consequences whatsoever arising from use of the information contained in this web site. The accessing of information contained in this web site shall under no circumstances be considered as creating an attorney-client relationship between Herzog and any party accessing this web site. Contacting through email any lawyer named in this web site or sending information without prior agreement of Herzog shall not be construed as automatically creating an attorney-client relationship between Herzog and the party sending an email or information. The material contained in this web site has been created by and remains the property of Herzog. No reproduction, transmission, publication or any other form of dissemination shall be permitted unless the prior written consent of Herzog has been obtained. This web site may contain links to other web sites operated by third parties. Herzog does not sponsor, approve or endorse the content of any such web site and is not responsible for the materials appearing in such sites.